Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
ET
- ET
FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the full year ended December 31, 2023, and highlighted progress of its pipeline. - As a result, Apollomics believes that its current capital resources will fund planned operations through the first quarter of 2025.
- Dr. Plunkett brings to Apollomics over 25 years of strategic and financial experience within the biopharmaceutical sector, including extensive fundraising and corporate development expertise.
- In March 2023, the Company raised $23.7 million in a private placement in public equity (PIPE) financing, before transaction expenses.